Effect of Short Term Atypical Antipsychotic Administration Compared to Placebo on Hepatic Insulin Extraction
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
Within the past 20 years, there has been a striking increase in the incidence of obesity 1;2,
type 2 diabetes mellitus (T2DM) 3-5, and cardiovascular diseases (CVD) in the schizophrenic
population 6-8 . Large NIH-funded trials indicate that the prevalence of metabolic syndrome
is twice to three times greater in schizophrenic patients on a specific class of drug termed
the "atypical antipsychotics" (AAPs), of which olanzapine is an example, as compared to
matched controls 8. Identification of the pathophysiological mechanisms contributing to
metabolic disease in schizophrenic patients on AAPs has been hampered by the inability to
differentiate underlying disease from treatment-emergent complications. In addition, despite
falling within the same drug class, different AAPs exhibit differential associations with
metabolic disease. Olanzapine is one of the AAPs associated with the greatest weight gain and
degree of metabolic impairments.